ClinicalTrials.gg
CompletedNCT07800533Updated Sep 2, 2026

Brivaracetam Bioequivalence Assessment

A Phase 1 interventional study of Briveka ® 100 mg and Briviact® 100 mg in Bioequivalence Study in Healthy Subjects, sponsored by Zodiac Produtos Farmaceuticos S.A.. Completed at 1 site in Brazil. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Zodiac Produtos Farmaceuticos S.A. · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Aug 2024, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study assess the relative bioavailability performance of a test brivaracetam coated tablets compared with the EMA reference product, Briviact® 100 mg, in healthy adult volunteers of both sexes under fasting conditions. The pharmacokinetic profiles will be compared to assess whether the test product demonstrates equivalent rate and extent of absorption to the reference formulation.

02

Conditions studied

  • Bioequivalence Study in Healthy Subjects
03

In context

Lead sponsor

Zodiac Produtos Farmaceuticos S.A. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18.5 and 30.0 kg/m². Non-smokers or former smokers who stopped smoking at least 1 year prior to screening.

Clinically healthy based on medical history, physical examination, vital signs, , and clinical laboratory tests.

Negative screening for , , and . Female participants must not be pregnant or breastfeeding and must have a negative pregnancy test.

No hair, wounds, or dermatological conditions at the intended patch application site (upper arm).

Able to understand the study procedures and provide written

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, hepatic, renal, gastrointestinal, neurological, psychiatric, metabolic, pulmonary, or dermatological diseases.
  • Known to rivastigmine, carbamate derivatives, or any component of the study formulation.
  • Abnormal clinical laboratory results, vital signs, or considered clinically significant by the investigator.
  • Positive test results for drugs of abuse, alcohol misuse, , , or .
  • Use of prescription or non-prescription medications that could interfere with the study drug within a defined period prior to dosing, as determined by the investigator.
  • Participation in another clinical trial or exposure to an drug within the previous 6 months.
  • Blood donation or significant blood loss within 3 months prior to the study.
  • Consumption of grapefruit-containing products, alcohol, or substances that could interfere with drug metabolism prior to dosing.
  • Use of medications known to significantly affect hepatic metabolism.
  • Positive or suspected infection with SARS-CoV-2 prior to study periods.
  • Any condition that, in the investigator's judgment, could interfere with study participation or the interpretation of study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Test

    Single oral dose administration of the test formulation Briveka® (brivaracetam coated tablets) 100 mg

    Drug: Briveka ® 100 mg

  • Active comparator
    Comparator

    Single oral dose administration of the reference formulation Briviact® (brivaracetam coated tablets) 100 mg

    Drug: Briviact® 100 mg

Interventions

  • DrugBriveka ® 100 mg

    Brivaracetam coated tablets

    Also known as: Test

  • Brivaracetam coated tablets

    Also known as: Comparator

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed plasma concentration of brivaracetam following a single-dose.

    Time frame: Up to 48 hours after drug administration

  2. AUC0-t

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration of brivaracetam.

    Time frame: Up to 48 hours after drug administration

07

Study locations

1 site
  • Unidade Integrada de Farmacologia e Gastroenterologia (UNIFAG)
    Bragança Paulista, São Paulo 12916-900, Brazil
08

References and documents

Publications

  • Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013 Jan;54(1):89-97. doi: 10.1111/j.1528-1167.2012.03598.x. Epub 2012 Jul 19. PubMed 22813235 ↗
  • Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007 Jun;63(6):680-8. doi: 10.1111/j.1365-2125.2006.02829.x. Epub 2007 Jan 12. PubMed 17223857 ↗
  • Otoul C, Watanabe S, McCabe S, Stockis A. Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet. Clin Pharmacol Drug Dev. 2017 May;6(3):313-317. doi: 10.1002/cpdd.275. Epub 2016 Jun 28. No abstract available. PubMed 27274002 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to confidentiality restrictions and institutional policies regarding participant-level clinical data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Aug 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 2, 2026
StartActual
Aug 9, 2024
Primary completionActual
Aug 16, 2024
CompletionActual
Aug 19, 2024
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07800533
Lead sponsor
Zodiac Produtos Farmaceuticos S.A.
Responsible party
Sponsor
First posted
Sep 2, 2026
Start date
Aug 9, 2024
Primary completion
Aug 16, 2024
Completion
Aug 19, 2024
Last update
Sep 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion